{"DataElement":{"publicId":"3226239","version":"1","preferredName":"Complete Remission At End Second Course Therapy Status","preferredDefinition":"The remission status at the end of the second course of therapy determined by morphologic evaluation of marrow; <5% blast = CR","longName":"3226238v1.0:3226233v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3226238","version":"1","preferredName":"Complete Remission At End Second Course Therapy","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured._Used to indicate position, location, or state (American Heritage Dictionary)_The point or place at which something terminates in time, space, or extent._Coming next after the first in position in space or time or degree or magnitude._A period of protocol-prescribed activity or intervention._An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"2739632v1.0:3226236v1.0","context":"NCIP","contextVersion":"1","ObjectClass":{"publicId":"2739632","version":"1","preferredName":"CR","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","longName":"C4870","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A8A6C36-5B39-6195-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-04-10","endDate":null,"createdBy":"CZECHS","dateCreated":"2008-04-10","modifiedBy":"ONEDATA","dateModified":"2008-04-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3226236","version":"1","preferredName":"At End Second Course Therapy","preferredDefinition":"Used to indicate position, location, or state (American Heritage Dictionary):The point or place at which something terminates in time, space, or extent.:Coming next after the first in position in space or time or degree or magnitude.:A period of protocol-prescribed activity or intervention.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"3226236v1.0","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"At","conceptCode":"C25427","definition":"Used to indicate position, location, or state.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"End","conceptCode":"C25496","definition":"The point or place at which something terminates in time, space, or extent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Second","conceptCode":"C25666","definition":"Coming next after the first in position in space or time or degree or magnitude.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Course","conceptCode":"C25379","definition":"Passage through time; duration; a systematic or/and orderly succession; a sequence, e.g. course of treatment; a mode of action or behavior; natural development, typical manner of proceeding.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A05B367B-79E5-4F90-E040-BB89AD43189F","latestVersionIndicator":"Yes","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"ONEDATA","dateModified":"2011-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A05B367B-79F6-4F90-E040-BB89AD43189F","latestVersionIndicator":"Yes","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"Released per approval from T.Davidsen. mc 4/18/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3226233","version":"1","preferredName":"Acute Myeloid Leukemia Remission Status","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003_An abatement in intensity or degree (as in the manifestations of a disease)._A condition or state at a particular time.","longName":"3226233v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"15","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"death","valueDescription":"Death","ValueMeaning":{"publicId":"2956827","version":"1","preferredName":"Death","longName":"2956827","preferredDefinition":"The absence of life or state of being dead.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CASP1 Gene","conceptCode":"C26554","definition":"This gene plays a role in apoptosis, inflammation, septic shock, and wound healing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"77039323-3A1F-00CF-E040-BB89AD43795B","latestVersionIndicator":"Yes","beginDate":"2009-10-28","endDate":null,"createdBy":"MAESKEB","dateCreated":"2009-10-28","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A05B367B-7967-4F90-E040-BB89AD43189F","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"ONEDATA","dateModified":"2011-04-07","deletedIndicator":"No"},{"value":"unevaluable","valueDescription":"Unevaluable","ValueMeaning":{"publicId":"3153578","version":"1","preferredName":"Unevaluable","longName":"3153578","preferredDefinition":"Unable to be evaluated.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unevaluable","conceptCode":"C62222","definition":"Unable to be evaluated.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"93AC689E-5DB2-5D7A-E040-BB89AD430948","latestVersionIndicator":"Yes","beginDate":"2010-10-28","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-10-28","modifiedBy":"KUMMEROA","dateModified":"2023-04-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A05B367B-797C-4F90-E040-BB89AD43189F","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"ONEDATA","dateModified":"2011-04-07","deletedIndicator":"No"},{"value":"not in CR","valueDescription":"Negation Complete Remission","ValueMeaning":{"publicId":"3076259","version":"1","preferredName":"Negation Complete Remission","longName":"3076259","preferredDefinition":"An operation in which a term denies or inverts the meaning of another term or construction.: The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Negation","conceptCode":"C25594","definition":"An operation in which a term denies or inverts the meaning of another term or construction.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8524736D-BB6E-7170-E040-BB89AD430519","latestVersionIndicator":"Yes","beginDate":"2010-04-26","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-04-26","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A05B367B-7991-4F90-E040-BB89AD43189F","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"ONEDATA","dateModified":"2011-04-07","deletedIndicator":"No"},{"value":"CR","valueDescription":"Complete Remission","ValueMeaning":{"publicId":"2577915","version":"1","preferredName":"Complete Remission","longName":"2577915","preferredDefinition":"The disappearance of all signs of cancer in response to treatment.  This does not always mean the cancer has been cured.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Complete Remission","conceptCode":"C4870","definition":"The disappearance of all signs of cancer in response to treatment.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-FD68-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-24","endDate":null,"createdBy":"REEVESD","dateCreated":"2006-02-24","modifiedBy":"ONEDATA","dateModified":"2006-02-24","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"A05B367B-799C-4F90-E040-BB89AD43189F","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"ONEDATA","dateModified":"2011-04-07","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2842596","version":"1","preferredName":"Outcome of Therapy","preferredDefinition":"The result of therapy for a given disease or condition in a patient or group of patients.","longName":"C18919 ","context":"NCIP","contextVersion":"1","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"63D982FA-DFBF-58C7-E040-BB89AD433E84","latestVersionIndicator":"Yes","beginDate":"2009-02-26","endDate":null,"createdBy":"CURTIST","dateCreated":"2009-02-26","modifiedBy":"CURTIST","dateModified":"2009-02-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3226232","version":"1","preferredName":"Acute Myeloid Leukemia Remission Status","preferredDefinition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues.  The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities 2) AML with multilineage dysplasia 3) Therapy-related AML 4) AML not otherwise categorized.  The required bone marrow or peripheral blood blast percentage for the diagnosis of AML has been recently reduced from 30% (French-American-British [FAB] classification) to 20% (WHO classification).  (WHO, 2001) -- 2003:An abatement in intensity or degree (as in the manifestations of a disease).:A condition or state at a particular time.","longName":"C3171:C18246:C25688","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acute Myeloid Leukemia","conceptCode":"C3171","definition":"A clonal expansion of myeloid blasts in the bone marrow, blood or other tissues. The classification of acute myeloid leukemias (AMLs) encompasses four major categories: 1) AML with recurrent genetic abnormalities; 2) AML with multilineage dysplasia; 3) Therapy-related AML; 4) AML not otherwise specified. The required bone marrow or peripheral blood blast percentage for the diagnosis of AML is 20% (WHO classification).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Remission","conceptCode":"C18246","definition":"An abatement in intensity or degree (as in the manifestations of a disease).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Status","conceptCode":"C25688","definition":"A condition or state at a particular time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A05B367B-7937-4F90-E040-BB89AD43189F","latestVersionIndicator":"Yes","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"ONEDATA","dateModified":"2011-04-07","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A05B367B-7948-4F90-E040-BB89AD43189F","latestVersionIndicator":"Yes","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"COOPERM","dateModified":"2011-04-18","changeDescription":"Released per approval of T.Davidsen. mc 4/18/11","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"5650570","version":"1","longName":"TARGET","context":"OCG","ClassificationSchemeItems":[{"publicId":"5650572","version":"1","longName":"AML","context":"OCG"}]}],"AlternateNames":[{"name":"OCG","type":"USED_BY","context":"OCG"}],"ReferenceDocuments":[{"name":"Morphologic CR status at end","type":"Preferred Question Text","description":"Morphologic CR status at end of course 2","url":null,"context":"NCIP"},{"name":"Original TARGET Question","type":"Alternate Question Text","description":"CR status at end of course 2","url":null,"context":"NCIP"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A05B367B-7A13-4F90-E040-BB89AD43189F","latestVersionIndicator":"Yes","beginDate":"2011-04-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2011-04-07","modifiedBy":"COOPERM","dateModified":"2017-02-02","changeDescription":"Released per approval from T.Davidsen. mc 4/18/11 Updated definition and question text per request by Tanja. mc 12/23/15","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}